Literature DB >> 9260238

Intensive pulse therapies for focal glomerulosclerosis in South African children.

M Adhikari1, R Bhimma, H M Coovadia.   

Abstract

Seven children with steroid-resistant focal segmental glomerulosclerosis (SR-FGS) were placed on a therapeutic protocol of methylprednisolone (MP), oral prednisone (pred) and oral cyclophosphamide (CYC) given over 16 months (regimen A). Another 5 children with SR-FGS were treated with a shorter course of intravenous CYC (monthly doses over 6 months), intravenous MP (3 consecutive daily doses) and oral pred 2 mg/kg (alternate days) (regimen B). With regimen A, 1 child had a short remission, and in the others, oedema subsided, the urine protein/ creatinine ratio decreased, haematuria disappeared and the estimated glomerular filtration rate (GFR) increased. The observation period was 21-42 months and the drugs were well tolerated. With regimen B, 2 patients went into complete remission, 1 had partial remission, 1 failed to respond and another died because of severe concurrent infections. In the responding children, oedema cleared, the urine protein/ creatinine ratio decreased, haematuria disappeared and the GFR rose. The follow-up was between 3 and 34 months. Minor side effects were alopecia and transient hypertension. Both regimens improved the quality of life of most children. Compared with regimen A, regimen B is six times less costly with a quarter of the number of hospital visits. These observations may be of value in designing appropriate multicentre controlled trials, which have been advocated recently, for the rational and optimum management of SR-FGS.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9260238     DOI: 10.1007/s004670050309

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  8 in total

1.  Steroid-resistant nephrotic syndrome: the influence of race on cyclophosphamide sensitivity.

Authors:  Rajendra Bhimma; Miriam Adhikari; Kareshma Asharam
Journal:  Pediatr Nephrol       Date:  2006-09-12       Impact factor: 3.714

2.  Intravenous cyclophosphamide in steroid-resistant nephrotic syndrome.

Authors:  Anurag Bajpai; Arvind Bagga; Pankaj Hari; Amit Dinda; Rajendra N Srivastava
Journal:  Pediatr Nephrol       Date:  2003-03-21       Impact factor: 3.714

Review 3.  Mycophenolate mofetil therapy in frequently relapsing steroid-dependent and steroid-resistant nephrotic syndrome of childhood: current status and future directions.

Authors:  Asha Moudgil; Arvind Bagga; Stanley C Jordan
Journal:  Pediatr Nephrol       Date:  2005-06-24       Impact factor: 3.714

4.  Treatment with Cyclophosphamide for steroid-resistant nephrotic syndrome in children.

Authors:  Florentina Cucer; Ingrith Miron; Robert Müller; Codruta Iliescu Halitchi; Doina Mihaila
Journal:  Maedica (Buchar)       Date:  2010-07

5.  Efficacy of intravenous pulse cyclophosphamide treatment versus combination of intravenous dexamethasone and oral cyclophosphamide treatment in steroid-resistant nephrotic syndrome.

Authors:  Mukta Mantan; Chenni S Sriram; Pankaj Hari; Amit Dinda; Arvind Bagga
Journal:  Pediatr Nephrol       Date:  2008-06-20       Impact factor: 3.714

Review 6.  Corticosteroid-resistant nephrotic syndrome with focal and segmental glomerulosclerosis : an update of treatment options for children.

Authors:  Jochen H H Ehrich; Lars Pape; Mario Schiffer
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

7.  Efficacy and Safety of Immunosuppressive Therapy in Primary Focal Segmental Glomerulosclerosis: A Systematic Review and Meta-analysis.

Authors:  Dawn J Caster; Barbara Magalhaes; Natali Pennese; Andrea Zaffalon; Marina Faiella; Kirk N Campbell; Jai Radhakrishnan; Vladmir Tesar; Howard Trachtman
Journal:  Kidney Med       Date:  2022-06-11

8.  A Randomized Controlled Trial of Intravenous versus Oral Cyclophosphamide in Steroid-resistant Nephrotic Syndrome in Children.

Authors:  K M Shah; A J Ohri; U S Ali
Journal:  Indian J Nephrol       Date:  2017 Nov-Dec
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.